Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 11:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 75 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
RA
Interventions
Sarilumab, Auto-Injector Device (AID), Pre-filled Syringe (PFS), Methotrexate, Sulfasalazine, Leflunomide, Hydroxychloroquine
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
31
States / cities
Huntsville, Alabama • Peoria, Arizona • Roseville, California + 25 more
Conditions
Chronic Urticaria
Interventions
TEV-45779, XOLAIR® Injection
Combination Product
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 75 Years
Enrollment
608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
9
States / cities
Bakersfield, California • Clearwater, Florida • Coral Gables, Florida + 6 more
Conditions
Healthy Volunteers
Interventions
Risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 60 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Cypress, California • Grayslake, Illinois
Conditions
Healthy Volunteers
Interventions
Etrolizumab, Auto-Injector (AI), Prefilled Syringe With Needle Safety Device (PFS-NSD)
Drug · Device
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
4
States / cities
Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas + 1 more
Conditions
Healthy Volunteers
Interventions
SHP643
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Miami, Florida
Conditions
Anaemia
Interventions
Daprodustat, Darbepoetin alfa, Iron therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 99 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
36
States / cities
Anaheim, California • Cerritos, California • Escondido, California + 31 more
Conditions
Psoriasis
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
8
States / cities
Ocala, Florida • Rolling Meadows, Illinois • Plainfield, Indiana + 5 more
Conditions
Healthy Volunteers
Interventions
Vedolizumab SC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
Crohn's Disease
Interventions
Andecaliximab, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
33
States / cities
Dothan, Alabama • Scottsdale, Arizona • Los Angeles, California + 30 more
Conditions
Osteoporosis, Postmenopausal
Interventions
TVB-009, Prolia®
Combination Product
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
60 Years to 90 Years · Female only
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
20
States / cities
Phoenix, Arizona • Tucson, Arizona • San Diego, California + 17 more
Conditions
Primary Hypercholesterolemia, Mixed Dyslipidemia
Interventions
Evolocumab Pre-filled Syringe, Evolocumab AI/pen
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
21
States / cities
Encino, California • Thousand Oaks, California • Ventura, California + 17 more
Conditions
Neovascular Age Related Macular Degeneration
Interventions
RTH258
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
3
States / cities
Altamonte Springs, Florida • Pensacola, Florida • Richmond, Virginia
Conditions
Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD)
Interventions
aflibercept 8 mg PFS
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
2
States / cities
Bellaire, Texas • The Woodlands, Texas
Conditions
Thyroid Eye Disease
Interventions
Efgartigimod PH20 SC, Placebo PH20 SC
Combination Product · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
11
States / cities
Los Angeles, California • Mission Hills, California • Rancho Cordova, California + 8 more
Conditions
Healthy, Multiple Sclerosis
Interventions
BIIB017 (peginterferon beta-1a) Pre-filled syringe (PFS), BIIB017 (peginterferon beta-1a) Autoinjector
Device
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 45 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Saint Paul, Minnesota
Conditions
Neovascular (Wet) Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, Diabetic Retinopathy
Interventions
SCD411 0.05mL (2mg)
Drug
Lead sponsor
Sam Chun Dang Pharm. Co. Ltd.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
4
States / cities
Stuart, Florida • Winter Haven, Florida • Lemont, Illinois + 1 more
Conditions
Early Stage Breast Cancer
Interventions
Denosumab
Drug
Lead sponsor
Hope Rugo, MD
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
San Francisco, California
Conditions
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
Interventions
Faricimab PFS Configuration
Combination Product
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Mesa, Arizona • Phoenix, Arizona
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Two Formulations of LY3074828 in Healthy Participants

NCT03662100
Conditions
Healthy
Interventions
LY3074828, LY3074828, Auto-injector (AI), Prefilled syringe (PFS)
Biological · Drug · Device
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Daytona Beach, Florida
Conditions
IgA Nephropathy (IgAN), Renal and Urinary Disorders, Berger Disease
Interventions
Atacicept 150 mg
Drug
Lead sponsor
Vera Therapeutics, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
Brisbane, California
Conditions
NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis
Interventions
Satralizumab, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
17
States / cities
Birmingham, Alabama • La Jolla, California • Newport Beach, California + 12 more
Conditions
Neovascular Age-related Macular Degeneration (nAMD)
Interventions
SOK583A1 (40 mg/mL), Prefilled Syringe (PFS)
Drug · Device
Lead sponsor
Sandoz
Industry
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Marietta, Georgia • Oak Forest, Illinois • Liverpool, New York
Conditions
Angioedema
Interventions
Placebo, Lanadelumab
Other · Drug
Lead sponsor
Takeda
Industry
Eligibility
12 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
20
States / cities
Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 17 more
Conditions
Autoimmune Encephalitis (AE)
Interventions
Efgartigimod PH20 (ARGX-113) SC, Placebo PH20 SC
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
12 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
2
States / cities
Tucson, Arizona • Sherman, Texas